FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Cooke Shane
  2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ALKS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
CONNAUGHT HOUSE, 1 BURLINGTON ROAD		 3. Date of Earliest Transaction (Month/Day/Year)
05/31/2024
(Street)

DUBLIN 4 Ireland		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) (1) $ 69.83 11/17/2023   J V 1,102     (2) 02/26/2025 Ordinary Shares 1,102 $ 69.83 56,227 D  
Employee Stock Option (Right to Buy) (1) $ 31.64 11/17/2023   J V 1,200     (2) 02/28/2026 Ordinary Shares 1,200 $ 31.64 61,200 D  
Employee Stock Option (Right to Buy) (1) $ 53.5 11/17/2023   J V 425     (2) 02/17/2027 Ordinary Shares 425 $ 53.5 21,675 D  
Non Qualified Stock Option (Right to Buy) (1) $ 44.75 11/17/2023   J V 520     (2) 05/23/2028 Ordinary Shares 520 $ 44.75 26,520 D  
Non Qualified Stock Option (Right to Buy) (1) $ 44.75 11/17/2023   J V 350     (2) 05/23/2028 Ordinary Shares 350 $ 44.75 17,850 D  
Non Qualified Stock Option (Right to Buy) (1) $ 24.55 11/17/2023   J V 448     (2) 05/22/2029 Ordinary Shares 448 $ 24.55 22,848 D  
Non Qualified Stock Option (Right to Buy) (1) $ 16.52 11/17/2023   J V 256     (2) 05/20/2030 Ordinary Shares 256 $ 16.52 13,079 D  
Non Qualified Stock Option (Right to Buy) (1) $ 18.45 11/17/2023   J V 230     (2) 12/02/2030 Ordinary Shares 230 $ 18.45 11,739 D  
Non Qualified Stock Option (Right to Buy) (1) $ 24.24 11/17/2023   J V 313     (2) 06/14/2031 Ordinary Shares 313 $ 24.24 15,990 D  
Non Qualified Stock Option (Right to Buy) (1) $ 30.86 11/17/2023   J V 231     (2) 07/07/2032 Ordinary Shares 231 $ 30.86 11,785 D  
Non Qualified Stock Option (Right to Buy) (1) $ 30.72 11/17/2023   J V 254   06/29/2024(3) 06/29/2033 Ordinary Shares 254 $ 30.72 12,986 D  
Restricted Stock Unit Award (1) (4) 11/17/2023   J V 119   06/29/2024(5)   (5) Ordinary Shares 119 (4) 6,104 D  
Restricted Stock Unit Award (4) 05/31/2024   A   8,013   05/31/2025(6)   (6) Ordinary Shares 8,013 $ 0 8,013 D  
Non Qualified Stock Option (Right to Buy) $ 23.4 05/31/2024   A   17,492   05/31/2025(7) 05/31/2034 Ordinary Shares 17,492 $ 0 17,492 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Cooke Shane
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN 4 Ireland		   X      

Signatures

 /s/ Shantale Greenson, attorney-in-fact for Shane Cooke   06/04/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
(2) These options are fully vested in accordance with their terms.
(3) Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
(4) Each restricted stock unit represents a contingent right to receive one ordinary share.
(5) Shares subject to the restricted stock unit award vest in full on 6/29/2024.
(6) Shares subject to the restricted stock unit award vest in full on 5/31/2025.
(7) Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.
 
Remarks:
EXHIBIT LIST: Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.